Related Experiment Video

Updated: Jun 9, 2026

Semiconductor Sequencing for Preimplantation Genetic Testing for Aneuploidy
09:03

Semiconductor Sequencing for Preimplantation Genetic Testing for Aneuploidy

Published on: August 25, 2019

[Prediction of adverse pregnancy outcome by first-trimester maternal serum PAPP-A]

V Stoikova, St Ivanov

    Akusherstvo I Ginekologiia
    |August 26, 2010
    PubMed

    Preeclampsia occurs in 2 to 5% of all pregnancies in developed countries. Together with IUGR it consists one of the leading reasons for perinatal death and childhood handicap. This is why many authors are looking for a widely usable and easy to perform test for evaluation of the patients at risk for preeclampsia an IUGR. PAPP-A is a protein complex produced by the developing trophoblast which is used as a marker for Downs' syndrome. Previous studies have shown an association between low first trimester maternal serum PAPP-A and subsequent development of pregnancy complications.

    Related Concept Videos

    Teratogenicity01:07

    Teratogenicity

    The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...